補(bǔ)體成分3a(C3a)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Complement Component 3a (C3a)
- 編號(hào)SEA387Ca
- 物種Canis familiaris; Canine (Dog，犬) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍3.12-200ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于1.24ng/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 3024 ¥ 4320 ¥ 19440 ¥ 36720 ¥ 302400
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)補(bǔ)體成分3a(C3a)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的補(bǔ)體成分3a(C3a)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 86-95 | 90 |
| EDTA plasma(n=5) | 83-93 | 87 |
| heparin plasma(n=5) | 94-101 | 97 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的補(bǔ)體成分3a(C3a)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中補(bǔ)體成分3a(C3a)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-94% | 94-102% | 78-98% | 82-92% |
| EDTA plasma(n=5) | 87-97% | 79-93% | 97-104% | 95-103% |
| heparin plasma(n=5) | 95-104% | 80-96% | 80-92% | 88-98% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將補(bǔ)體成分3a(C3a)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的補(bǔ)體成分3a(C3a)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的補(bǔ)體成分3a(C3a)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的補(bǔ)體成分3a(C3a)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Canis familiaris; Canine (Dog，犬) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA387Ca01 | 補(bǔ)體成分3a(C3a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA387Ca02 | 補(bǔ)體成分3a(C3a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA387Ca01 | 補(bǔ)體成分3a(C3a)多克隆抗體 | WB; IHC; ICC; IP. |
| SEA387Ca | 補(bǔ)體成分3a(C3a)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA387Ca | 補(bǔ)體成分3a(C3a)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| 22 | Immobilization of soluble complement receptor 1 on islets. [ScienceDirect: S0142961211002596] |
| Journal of Reproductive Immunology | Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia [PubMed: 23415845] |
| Journal of Antimicrobial Chemotherapy | Efficacy of a synthetic antimicrobial peptidomimetic versus vancomycin in a Staphylococcus epidermidis device-related murine peritonitis model [Pubmed: 23645587] |
| SpringerPlus | Therapeutic effects of sesame oil on monosodium urate crystal-induced acute inflammatory response in rats [Pubmed: 24353977] |
| Gynecol Obstet Invest | Complement Split Products C3a/C5a and Receptors: Are They Regulated by Circulating Angiotensin II Type 1 Receptor Autoantibody in Severe Preeclampsia? [PubMed: 26485247] |
| Am J Reprod Immunol | Human IgG Antinuclear Antibodies Induce Pregnancy Loss in Mice by Increasing Immune Complex Deposition in Placental Tissue: In Vivo Study [PubMed: 26388133] |
| Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis [Pubmed:27235358] |
| Plos One | Alternative Pathway Inhibition by Exogenous Factor H Fails to Attenuate Inflammation and Vascular Leakage in Experimental Pneumococcal Sepsis in Mice [Pubmed:26872035] |
| Digital Repository | Dosagem de fra??es ativadas do sistema complemento em empiema induzido em ratos [10183] |
| Colloids Surf B Biointerfaces. | Interaction of gold and silver nanoparticles with human plasma: Analysis of protein corona reveals specific binding patterns. [pubmed:28131092] |
| Pediatric Pulmonology | Accuracy of complement activation product levels to detect infected pleural effusion in rats [pubmed:28474458] |
| Journal of Immunology | The Complement C3a–C3aR Axis Promotes Development of Thoracic Aortic Dissection via Regulation of MMP2 Expression [Pubmed:29367209] |
| Artificial?Cells?Nanomedicine and Biotechnology Journal | Long term safety and immunological effects of a nanobiotherapeutic, bovine poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], after four weekly?… [Pubmed:29873524] |
| Cytotherapy | Mesenchymal stromal cell secretory factors induce sustained improvements in islet function pre-and post-transplantation [Doi: 10.1016/j.jcyt.2018.07.007] |
| Journal of?NeuroVirology | Intrathecal complement activation by the classical pathway in tick-borne encephalitis [Pubmed: 30850976] |
| Clinical Immunology | Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss [] |
| Materials Science and Engineering: C | Hemocompatibility of biodegradable Zn-0.8 wt%(Cu, Mn, Li) alloys [] |
| Nanomedicine | Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion [33549818] |
| EXPERIMENTAL EYE RESEARCH | Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression [33493474] |
| FASEB J | C‐reactive protein inhibits C3a/C3aR‐dependent podocyte autophagy in favor of diabetic kidney disease [Pubmed:35503088] |
